Oluyemi Okupe Sells 12,313 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,313 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $28.82, for a total transaction of $354,860.66. Following the transaction, the chief financial officer owned 251,804 shares of the company’s stock, valued at approximately $7,256,991.28. This represents a 4.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Trading Up 0.4%

Hims & Hers Health stock traded up $0.11 during mid-day trading on Friday, hitting $28.00. 9,354,183 shares of the company’s stock were exchanged, compared to its average volume of 24,392,793. The company’s 50 day simple moving average is $30.19 and its 200-day simple moving average is $27.60. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm has a market capitalization of $6.53 billion, a P/E ratio of -44.45 and a beta of 2.42. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the firm posted $0.17 earnings per share. The firm’s revenue was up 38.2% on a year-over-year basis. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares during the period. State of Michigan Retirement System increased its holdings in shares of Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after acquiring an additional 280,900 shares during the last quarter. Norges Bank acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $62,153,000. Finally, Clear Street Group Inc. raised its stake in Hims & Hers Health by 23.6% in the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after acquiring an additional 363,893 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: COO Michael Chi sold 14,027 shares for approximately $398,000, and insider Soleil Boughton sold 6,236 shares for about $174,000. Both transactions were made under pre-arranged Rule 10b5-1 trading plans, limiting their value as direct signals of management’s current outlook, although the sales may still attract investor attention. SEC insider filing
• Negative Sentiment: Multiple investor-rights law firms publicized a securities class action against Hims & Hers and certain executives. The case covers investors who acquired HIMS securities from August 4, 2025, through July 29, 2026; the deadline to seek lead-plaintiff status is November 2, 2026. The repeated law-firm announcements appear to concern the same litigation rather than separate lawsuits. HIMS securities class action
• Negative Sentiment: The litigation alleges that Hims & Hers made materially misleading statements or omissions concerning privacy and data-sharing practices, billing, and other business conduct described in the FTC’s complaint. If the claims gain traction, potential consequences include legal costs, reputational damage, regulatory scrutiny, and pressure on future operating results. These allegations have not been proven in court. FTC-related lawsuit allegations

Analysts Set New Price Targets

A number of research firms recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Citigroup dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.